|A contemporary prostate cancer grading system: a validated alternative to the Gleason score|
JI Epstein, MJ Zelefsky, DD Sjoberg, JB Nelson, L Egevad, ...
European urology 69 (3), 428-435, 2016
|Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: the 15-year Johns Hopkins experience|
M Han, AW Partin, CR Pound, JI Epstein, PC Walsh
Urologic Clinics of North America 28 (3), 555-565, 2001
|Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer|
R Hu, TA Dunn, S Wei, S Isharwal, RW Veltri, E Humphreys, M Han, ...
Cancer research 69 (1), 16-22, 2009
|Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results|
KA Roehl, M Han, CG Ramos, JAV Antenor, WJ Catalona
The Journal of urology 172 (3), 910-914, 2004
|Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer|
M Han, AW Partin, M Zahurak, S Piantadosi, JI Epstein, PC Walsh
The Journal of urology 169 (2), 517-523, 2003
|Prostate cancer–specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy|
BJ Trock, M Han, SJ Freedland, EB Humphreys, TL DeWeese, AW Partin, ...
Jama 299 (23), 2760-2769, 2008
|Predicting 15-year prostate cancer specific mortality after radical prostatectomy|
SE Eggener, PT Scardino, PC Walsh, M Han, AW Partin, BJ Trock, Z Feng, ...
The Journal of urology 185 (3), 869-875, 2011
|Prostate specific antigen best practice statement: 2009 update|
KL Greene, PC Albertsen, RJ Babaian, HB Carter, PH Gann, M Han, ...
The Journal of urology 189 (1), S2-S11, 2013
|Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies|
SD Kundu, KA Roehl, SE Eggener, JAV Antenor, M Han, WJ Catalona
The Journal of urology 172 (6 Part 1), 2227-2231, 2004
|An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011|
JB Eifler, Z Feng, BM Lin, MT Partin, EB Humphreys, M Han, JI Epstein, ...
BJU international 111 (1), 2013
|PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients|
TL Lotan, B Gurel, S Sutcliffe, D Esopi, W Liu, J Xu, JL Hicks, BH Park, ...
Clinical cancer research 17 (20), 6563-6573, 2011
|Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer|
M Han, AW Partin, S Piantadosi, JI Epstein, PC Walsh
The Journal of urology 166 (2), 416-419, 2001
|Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death|
R Na, SL Zheng, M Han, H Yu, D Jiang, S Shah, CM Ewing, L Zhang, ...
European urology 71 (5), 740-747, 2017
|Characteristics of prostate cancer detected by digital rectal examination only|
OT Okotie, KA Roehl, M Han, S Loeb, SN Gashti, WJ Catalona
Urology 70 (6), 1117-1120, 2007
|The role of anxiety in prostate carcinoma: a structured review of the literature|
W Dale, P Bilir, M Han, D Meltzer
Cancer: Interdisciplinary International Journal of the American Cancer …, 2005
|African American men with very low–risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them?|
D Sundi, AE Ross, EB Humphreys, M Han, AW Partin, HB Carter, ...
Journal of clinical oncology 31 (24), 2991, 2013
|Tissue-based genomics augments post-prostatectomy risk stratification in a natural history cohort of intermediate-and high-risk men|
AE Ross, MH Johnson, K Yousefi, E Davicioni, GJ Netto, L Marchionni, ...
European urology 69 (1), 157-165, 2016
|Radiofrequency lumbar facet denervation: analysis of prognostic factors|
RB North, M Han, M Zahurak, DH Kidd
Pain 57 (1), 77-83, 1994
|18F-DCFBC PET/CT for PSMA-based detection and characterization of primary prostate cancer|
SP Rowe, KL Gage, SF Faraj, KJ Macura, TC Cornish, ...
Journal of Nuclear Medicine 56 (7), 1003-1010, 2015
|The natural history and treatment of adrenal myelolipoma|
M Han, AL Burnett, EK Fishman, FF Marshall
The Journal of urology 157 (4), 1213-1216, 1997